Bone Therapeutics raises €7.7m to progress PhIII PREOB, with plans for more
This article was originally published in Scrip
Executive Summary
Belgian biopharmaceutical company Bone Therapeutics has closed a series D funding round raising €7.7 million, which the company will use to sustain its two Phase III trials with lead product PREOB.